Toxicity and Immunogenicity of a Tardigrade Cytosolic Abundant Heat Soluble Protein in Mice

Harrison J. Esterly1,2, Candice J. Crilly2, Samantha Piszkiewicz2, Dane J. Shovlin1, Gary J. Pielak2,3,4,5 and Brooke E. Christian1*

1 Department of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, United States, 2 Department of Chemistry, University of North Carolina, Chapel Hill, NC, United States, 3 Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, United States, 4 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States, 5 Integrative Program for Biological and Genome Sciences, University of North Carolina, Chapel Hill, NC, United States

Tardigrades are microscopic animals well-known for their stress tolerance, including the ability to survive desiccation. This survival requires cytosolic abundant heat soluble (CAHS) proteins. CAHS D protects enzymes from desiccation- and lyophilization-induced inactivation in vitro and has the potential to stabilize protein-based therapeutics, including vaccines. Here, we investigate whether purified recombinant CAHS D causes hemolysis or a toxic or immunogenic response following intraperitoneal injection in mice. CAHS D did not cause hemolysis, and all mice survived the 28-day monitoring period. The mice gained weight normally and developed anti-CAHS D antibodies but did not show upregulation of the inflammatory cytokines interleukin-6 and tumor necrosis factor alpha. In summary, CAHS D is not toxic and does not promote an inflammatory immune response in mice under the conditions used here, suggesting the reasonability of further study for use as stabilizers of protein-based therapeutics.

Keywords: cytosolic-abundant heat-soluble proteins, immunogenicity, intrinsically disordered proteins, protein-based therapeutics, tardigrades, toxicity

INTRODUCTION

The emergence of the novel coronavirus SARS-CoV-2 has caused a global outbreak in coronavirus disease 2019 (Ahn et al., 2020). There is an acute need for a vaccine for this virus, and formulations are currently under development (Ahn et al., 2020; Shanmugaraj et al., 2020). However, once a vaccine is available, production challenges will be accompanied by difficulties in distribution, especially in developing countries. The preservation of protein structure and activity requires careful handling and low temperatures, which increases storage and transportation costs (Lee et al., 2017).
The 2018 Ebola outbreak in the Democratic Republic of the Congo illustrated the hurdles that must be overcome for refrigeration during storage, transport, and distribution of peptide-based therapeutics (Ashok et al., 2017). The Ebola vaccine must be stored at −60°C or below to prevent spoilage, and an emergency increase in cold chain capacity has been a priority since 2014 (Jusu et al., 2018).

In addition to vaccines, there are more than 200 FDA-approved protein- and peptide-based therapeutics on the market, including treatments for type 2 diabetes, breast cancer, and prostate cancer (Fosgerau and Hoffmann, 2015; Usmani et al., 2017). To stabilize proteins and increase shelf life, sugars, polymers, amino acids, globular proteins, and osmolytes have been investigated as excipients (Piszkiewicz and Pielak, 2019). Even in the presence of excipients, proteins must be kept at low temperatures. Lyophilization and desiccation can increase the shelf life of some proteins but may lead to problems such as aggregation and denaturation (Piszkiewicz and Pielak, 2019).

Efforts to stabilize proteins for dehydration and long-term storage at ambient temperatures have shown success with the tardigrade cystolic-abundant heat soluble D (CAHS D) protein (Boothby and Pielak, 2017; Boothby et al., 2017; Piszkiewicz et al., 2019). CAHS D is intrinsically disordered, unique to tardigrades, and protects the activity of lipoprotein lipase and lactate dehydrogenase from desiccation, heat, and lyophilization (Piszkiewicz et al., 2019). The ability of CAHS D to protect both lipases and dehydrogenases suggests that the protection mechanism is generic and may be applicable to protein vaccine antigens such as hemagglutinin.

The application of CAHS proteins as excipients would be financially important and allow areas with little to no electricity infrastructure access to life-saving protein-based therapeutics. There are, however, a number of potential problems with using proteins from foreign organisms in therapeutic formulations, including allergic reactions and acute inflammation following administration.

Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) are inflammatory cytokines whose expression increases within 2 to 4 h following activation of the innate immune response (Papadakis and Targan, 2000; Zganis et al., 2004; Grivennikov et al., 2005; U.S. Department of Health and Human Services (DHHS), 2014; Francisco et al., 2015). IL-6 is produced in response to inflammation and stresses such as infection (Tanaka et al., 2014). Changes induced by IL-6 expression are often monitored in routine tests for inflammation and include increases in platelet release and induction of proteins such as C-reactive protein (Tanaka et al., 2014). TNFα is a pro-inflammatory cytokine secreted by macrophages that mediates acute inflammation (Chu, 2013). TNFα is also highly expressed in response to endotoxins. In contrast to the acute immune response, activation of the adaptive immune response is less immediate and involves the production of anti-drug antibodies that can interfere with drug action and reduce efficacy (De Groot and Scott, 2007; Baker et al., 2010). We injected CAHS D into mice to identify potential adverse responses, including weight loss and expression of IL-6 and TNFα.

### Materials and Methods

**Protein Purification**

The expression and purification of CAHS D was carried out as described (Piszkiewicz et al., 2019). To summarize, the pET-28b plasmid encoding CAHS D (Boothby et al., 2017) was transformed into BL21 (DE3) *E. coli*. The bacteria were grown at 37°C until the optical density reached 0.6 at 600 nm. CAHS D expression was induced with 1 mM isopropyl-β-D-thiogalactoside (final concentration) for 3 h, after which cells were centrifuged at 4,500g for 25 min at 10°C. The supernatant was discarded, and the pellet was resuspended in 20 mM Tris pH 7.5, and stored at −20°C. Samples were thawed at 37°C and the cells were lysed by heat shock in boiling H2O for 15 min and then cooled to room temperature. Cooled suspensions were centrifuged at 15,000g for 45 min. The supernatant was diluted with an equal volume of buffer containing 8 M urea and 50 mM sodium acetate, pH 4.0, filtered through a 0.45-μm filter, and loaded onto a 5-ml FPLC cation exchange column (HiTrap SP HP, GE Healthcare). CAHS D was eluted over 29 column volumes with a salt gradient of 0 to 0.4 M NaCl in 8 M urea, 50 mM sodium acetate, pH 4.0. Fractions were analyzed by SDS-PAGE. Those containing pure CAHS D were pooled, transferred to 3,500 MWCO dialysis tubing (Fisher 68035), and dialyzed once against 20 mM Tris-HCl pH 7.5 and then six additional times against deionized H2O. Purified CAHS D was once again sterile filtered through a 0.45-μm filter, flash frozen, and lyophilized. Lyophilized CAHS D was resuspended in endotoxin-free PBS at a concentration of ~20 g/L and then underwent two rounds of endotoxin removal by mixing with High Capacity Endotoxin Removal Resin (Pierce) overnight. The final endotoxin level was <10 EU/ml (<1 EU/injection) as quantified with the Chromogenic Endotoxin Quant Kit (Thermo Scientific Pierce). Purified CAHS D was analyzed by mass spectrometry, and a single peak was identified at m/z of 25353 Da (Supplementary Figure 1). The expected m/z is 25485.3 Da. The removal of the N-terminal methionine during expression in *E. coli* explains the difference between the expected and observed molecular mass (Wingfield, 2017). The final protein concentration was verified with a Bradford assay.

**Animals**

C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine) and housed under standard laboratory conditions. Mice were bred and maintained in a temperature-controlled room with a 12-h light/dark cycle and provided standard chow and water ad libitum. Male and female mice were used indiscriminately. The welfare of all laboratory mice was monitored daily. All experiments were approved by the Appalachian State Institutional Animal Care and Use Committee.

**Statistical Analysis**

Responses were compared using a homoscedastic two-tailed t-test (* indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).
Hemolysis
Blood from 3-month-old mice was collected by cardiac puncture under anesthesia with isoflurane and transferred to heparinized tubes (BD). Red blood cells from whole blood were pelleted at 1,000g for 10 min and washed twice with 10 times the pellet volume of Lactated Ringer’s solution (100 mM NaCl, 30 mM sodium lactate, 4 mM KCl, 1 mM CaCl2, VetOne). The red blood cell pellet was resuspended in Lactated Ringer’s solution to a final volume of 0.8% (v/v).

Equal volumes of Lactated Ringer’s solution, CAHS D (1.25 g/L, 2.5 g/L, 5 g/L, 10 g/L), or 1% Triton X-100 (MilliporeSigma) were mixed with the 0.8% red blood cell suspension for 30 min with rotation. The range of concentrations used was chosen based on the amount of CAHS D required to stabilize enzymes in vitro (Piszkiewicz et al., 2019). Lactated Ringer’s solution was used as a negative control because it is considered safe and causes minimal hemolysis (Ansel and Gigandet, 1976). Triton X-100 (1% weight/volume) was used as a positive control because it lyses red blood cells (Deibler et al., 1959). The suspensions were pelleted at 1,000g for 10 min, the pellets were discarded, and the absorbance of the supernatant was measured at 404 nm in the plate reader. The hemolysis experiment was performed in triplicate with blood from each of three mice. Comparisons between Lactated Ringer’s solution or CAHS D and Triton X-100 were performed.

Toxicity of CAHS D and Anti-CAHS D Antibody Production
Mice were divided into four groups of six each and given 100 µL intraperitoneal injections at day 0 and day 21. The first group was given Lactated Ringer’s solution as a negative control. The next two groups were given low (1.25 g/L) or high (15 g/L) doses of CAHS D. The final group was given 0.05 g/L recombinant hemagglutinin protein (HA) from the influenza A H1N1 (A/ Puerto Rico/8/1934) flu virus (Sino Biological 11684-V08H). The protein HA is often used in flu vaccines to induce anti-HA antibody production without toxicity (Henry et al., 2019). The HA injections were negative controls to show the specificity of the anti-CAHS D antibodies. All mice were monitored over a 28-day period for signs of toxicity, including weight loss, hunched posture, or changes in respiration. Blood was collected by submandibular vein puncture at day 0, 14, 21, and 28, and serum was purified with serum separator tubes (Sarstedt) and stored at –80°C. Antibodies against CAHS D were determined by ELISA assay as described below. The experiment was repeated twice more, for a total of 18 mice per treatment group. For anti-CAHS D antibody production and weight changes, values from each of three mice. Comparisons between Lactated Ringer’s solution or HA sample were compared to PBS.

Innate Immune Response
Mice were divided into seven groups of two to three each and given 100 µL intraperitoneal injections of Lactated Ringer’s solution, 1.25 g/L CAHS D, 2.5 g/L CAHS D, 5.0 g/L CAHS D, 10 g/L CAHS D, 15 g/L CAHS D, or 1 g/L lipopolysaccharides (LPS) from E. coli O127:B8 (MilliporeSigma L3129). Lactated Ringer’s solution was used as a negative control, and LPS was given as a positive control. LPS induces IL-6 and TNFα (Beurel and Jope, 2009). Four hours post injection, blood was collected by submandibular vein or cardiac puncture under anesthesia using isoflurane. Serum was purified with serum separator tubes and stored at –80°C. Serum was analyzed for IL-6 and TNFα by ELISA assay as described below. IL-6 and TNFα are markers of the proinflammatory cascade and indicators of inflammatory stress (Institute of Medicine (U.S.). Committee on Military Nutrition Research. et al., 1997). The experiment was repeated for a total of five to seven mice per treatment. Values for each assay were compared to values of the LPS positive control.

ELISA Assay
To detect anti-CAHS D antibodies, each well in a MaxiSorp high binding ELISA plate (Invitrogen) was coated with 50 µL of 11 mg/L CAHS D in 0.1 M NaHCO3 buffer, pH 9.6, for 4 h and then blocked with 200 µL of 1% (v/v) casein (MilliporeSigma) overnight at 4°C. Mouse serum was diluted 1:200, and 50 µL of each sample was added to the plate in triplicate. The plate was incubated at 37°C for 1 h then washed four times with Dulbecco’s Phosphate Buffered Saline containing 1% (v/v) Tween 20 (PBS-T, MilliporeSigma). Donkey anti-mouse HRP antibody (GE Healthcare) was diluted 1:4000 and 50 µL was added to each well. The plate was incubated at 37°C for 30 min and washed four times with PBS-T. 1-Step Ultra 3,3′,5,5′-tetramethylbenzidine ELISA Substrate Solution (ThermoFisher Scientific) was warmed to room temperature and 50 µL was added to each well. The substrate was developed for 15 min in the dark and the reaction stopped with 50 µL of 2 M H2SO4. The absorbance was measured at 450 nm in the plate reader.

Levels of TNFα were quantified from serum samples with Mouse TNFα ELISA Kits (Boster and Invitrogen). Serum dilutions ranged from 1:5 to 1:10. The analytical sensitivity of the assay was 8 pg/ml (Invitrogen) and <1 pg/ml (Boster). Levels of IL-6 were quantified from serum samples with Mouse IL-6 ELISA Kits (Boster and Invitrogen). Serum dilutions ranged from 1:5 to 1:80. The analytical sensitivity of the assay was 4 pg/ml (Invitrogen) and <1 pg/ml (Boster).

RESULTS
Hemolysis
All CAHS D concentrations tested resulted in hemolysis at levels less than or similar to the negative control (Figure 1). Lactated Ringer’s solution. Lactated Ringer’s solution and all CAHS D concentrations elicited values less than the positive control, TX-100.

Production of Anti-CAHS D Antibodies and Animal Health
Mice were injected with CAHS D (1.25 or 15 g/L) at day zero and given a second injection at day 21, designed to mimic a vaccine booster. Over the 28-day monitoring period, CAHS D at 1.25 g/L and 15 g/L was recognized by the mouse immune system following injection and elicited anti-CAHS D antibodies in serum at levels higher than PBS (Figure 2A). Anti-CAHS D
antibody levels decreased at day 21, then increased following the booster injection. No significant difference in antibody levels was observed between the injection of 1.25 and 15 g/L CAHS D. No anti-CAHS D antibodies were produced in response to injection of buffer alone or the H1N1 hemagglutinin protein (HA), thus confirming the specificity of the ELISA assay (Figure 2A). No mice died during the study, had changes in ambulation, or lost weight due to CAHS D injection (Figure 2B).

Production of Inflammatory Cytokines

Neither TNFα (Figure 3A) nor IL-6 (Figure 3B) were detected in levels above the limit of quantification. As a positive control, lipopolysaccharide (purified endotoxin) injection resulted in an inflammatory response that was higher than that elicited by PBS or CAHS D.

DISCUSSION

CAHS D caused less hemolysis than Lactated Ringer’s solution, which is known to be safe for intravenous injection (Figure 1) (Iqbal et al., 2018). Hemolysis of red blood cells can be dangerous and is induced by toxins such as those secreted from bacteria or present in snake venom (Condrea et al., 1964; Sogawa et al., 2018). The lack of hemolysis by CAHS D suggests it does not harm the structural integrity of red blood cells.

The production of dose dependent anti-CAHS D antibodies suggests that CAHS D was recognized by the mouse immune system following injection. Although antibody levels began to decline by 21 days post-injection, re-injection of CAHS D caused a second rise in antibody levels (Figure 2A). The development of anti-drug antibodies can interfere with the action of protein-based therapeutics but antibodies against CAHS D would not interfere with its intended purpose because CAHS D is not intended for use as a therapeutic; it would be used only to stabilize other therapeutic proteins during transport and storage, prior to injection. A BLASTp search of non-redundant protein sequences shows that CAHS D shares insignificant identity (<5%, E value <10) with any human or mouse protein, suggesting a low likelihood that antibodies to CAHS D will cross-react with endogenous proteins.

One measure of the toxicity of pharmaceuticals is whether they cause stress to animals. For example, the chemotherapeutic drug topotecan causes mice to lose as much as 30% of their body...
In this study, mice were monitored for 28 days following injection of CAHS D and were re-injected at day 21. No mice died during the study, had changes in ambulation, or lost weight due to CAHS D injection (Figure 2B). All mice, including those injected with buffer alone, showed a 5% to 10% weight gain over a one-month period, which is typical for C57Bl/6J mice (Gargiulo et al., 2014) and consistent with changes in body weight with age for such mice maintained at The Jackson Laboratory, as stated in the Mouse Phenome Database, (http://www.jax.org/phenome). The typical weight gain and lack of obvious signs of stress suggest that CAHS D is safe for injection in mice.

The absence of TNFα and IL-6 induction following injection of CAHS D means that the mice did not initiate an inflammatory response to CAHS D and that efforts to remove endotoxins from the purified protein were successful. Taken together with the lack of hemolysis or weight loss induced by CAHS D, these results confirm that CAHS D does not illicit toxic or acute inflammatory immune responses in mice.

To be cost effective, the purification of CAHS D must be easy and have a high yield. One L of Escherichia coli expressing recombinant CAHS D can produce as much as 20 mg of purified CAHS D. However, removal of endotoxin is costly and time-consuming. It might be beneficial to optimize purification of CAHS D in insect cells or in endotoxin-free bacteria (Mamat et al., 2015; Planesse et al., 2015).

In conclusion, this study demonstrates that CAHS D does not cause hemolysis, notable distress, or an acute inflammatory response in mouse models. In vitro studies with enzymes indicate that lyophilization or desiccation with CAHS D can protect activity upon desiccation (Piszkiewicz et al., 2019). Future studies are needed to demonstrate that therapeutics stabilized with CAHS D remain effective following injection.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Appalachian State University Institutional Animal Care and Use Committee (IACUC).

**AUTHOR CONTRIBUTIONS**

HE and BC designed the study. HE, CC, SP, DS, and BC conducted experiments and analyses. HE wrote the first draft of the manuscript and prepared the figures. BC and GP obtained funding, contributed to study design and edited subsequent drafts. SP obtained funding, contributed to data interpretation and critically reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by a University of North Carolina System Stage II Inter-Institutional Planning Grant (IPG) to BC...
and GP and the National Institutes of Health (R01GM127291 to GP). SP was partially supported by a dissertation completion fellowship from the UNC Graduate School. CC was partially supported by a fellowship from the National Science Foundation (DGE-1650116) and a NIH Training Grant (T32GM008570).

ACKNOWLEDGMENTS

We thank the Appalachian State University Office of Student Research for support, Ellen Young and Lisa Lindesmith for help with assay design, Brandie Ehrmann of the UNC Chemistry Mass Spectrometry Core Laboratory for equipment maintenance and advice, Matthew Redinbo for use of the plate reader, and Elizabeth Pielak for comments on the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.565969/full#supplementary-material

REFERENCES

Ahn, D. G., Shin, H. J., Kim, M. H., Lee, S., Kim, H. S., Myoung, J., et al. (2020). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol. 30, 313–324. doi: 10.4104/jmib.2020.30011

Ansel, H. C., and Gigandet, M. P. (1976). Hemolysis of erythrocytes by primary pharmacologic agents, part 2: influence of the vehicle. Am. J. Hosp. Pharm. 33, 1264–1267. doi: 10.1093/ajhp/33.12.1264

Ashok, A., Brison, M., and Letallec, Y. (2017). Improving cold chain systems: Challenges and solutions. Vaccine 35, 2217–2223. doi: 10.1016/j.vaccine.2016.08.045

Baker, M. P., Reynolds, H. M., Lumicisi, B., and Bryson, C. J. (2010). Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonsel 1, 314–322. doi: 10.4161/self.1.4.13904

Beurel, E., and Jope, R. S. (2009). Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflamm. 6, 9. doi: 10.1186/1742-204-6-9

Boothby, T. C., and Pielak, G. J. (2017). Intrinsically Disordered Proteins and Desiccation Tolerance: Elucidating Functional and Mechanistic Underpinnings of Anhydrobiosis. Bioessays 39. doi: 10.1002/bies.201700119

Boothby, T. C., Tapia, H., Brozena, A. H., Piszkwiecz, S., Smith, A. E., Giovannini, I., et al. (2017). Tardigrades Use Intrinsically Disordered Proteins to Survive Desiccation. Mol. Cell 65, 975–984 e975. doi: 10.1016/j.molcel.2017.02.018

Chu, W. M. (2013). Tumor necrosis factor. Cancer Lett. 328, 222–225. doi: 10.1016/j.canlet.2012.10.014

De Groot, A. S., and Scott, D. W. (2013). Hemolysis of Human Erythrocytes by Escherichia Phospholipids by Snake Venom. Biochim. Biophys. Acta 84, 60–73. doi: 10.1016/j.bbapro.2010.01.003

Dean, E., Devries, A., and Mager, J. (1964). Hemolysis and Splitting of Human Hemolysis. Am. J. Hosp. Pharm. 11, 138–142. doi: 10.2146/ajhp.1964.11.1.138

Deng, X., An, C., Zhou, S., Xia, D., Yi, J., et al. (2019). Intrinsically Disordered Proteins and Desiccation Tolerance: Elucidating Functional and Mechanistic Underpinnings of Anhydrobiosis. Bioessays 39. doi: 10.1002/bies.201700119

Esterly et al. CAHS D Toxicity and Immunogenicity

Henry, C., Palm, A. E., Utset, H. A., Huang, M., Ho, I. Y., Zheng, N. Y., et al. (2019). Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study. J. Virol. 93. doi: 10.1128/JVI.01150-19

Institute of Medicine (U.S.). Committee on Military Nutrition Research, Newberry, S. J., Costello, R. B. (1997). Emerging technologies for nutrition research: potential for assessing military performance capability (Washington, D.C: National Academy Press).

Joyal, U., Anwar, H., and Scribani, M. (2018). Ringer’s lactate versus normal saline in acute pancreatitis: A systematic review and meta-analysis. J. Dig. Dis. 19, 335–341. doi: 10.1111/jid.12980.12606

Jusu, M. O., Glauser, G., Seward, J. F., Bawoh, M., Tempel, J., Friend, M., et al. (2018). Rapid Establishment of a Cold Chain Capacity of –60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone. J. Infect. Dis. 217, 548–555. doi: 10.1093/infdis/jix336

Lee, B. Y., Wedlock, P. T., Haidari, L. A., Elder, K., Potet, J., Manning, R., et al. (2017). Economic impact of thermostable vaccines. Vaccine 35, 3135–3142. doi: 10.1016/j.vaccine.2017.03.081

Mamat, U., Wilke, K., Branhill, D., Schromm, A. B., Lindner, B., Kohl, T. A., et al. (2015). Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microb. Cell Fact 14, 57. doi: 10.1186/s12934-015-0241-5

Papadakis, K. A., and Targan, S. R. (2000). Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119, 1148–1157. doi: 10.1053/gast.2000.18160

Piszkwiecz, S., and Pielak, G. J. (2019). Protecting Enzymes from Stress-Induced Inactivation. Biochemistry 58, 3825–3833. doi: 10.1021/acs.biochem.9b00675

Planesse, C., Nativel, B., Iwema, T., Gasque, P., Robert Da Silva, C., and Viraeniac, W. (2015). Recombinant human HSP60 produced in ClearColi BL21(DE3) does not activate the NFκB pathway. Cytokine 73, 190–195. doi: 10.1016/j.cyt.2015.01.028

Shah, D. K., and Balthasar, J. P. (2014). PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. Int. J. Pharm. 465, 228–238. doi: 10.1016/j.ijpharm.2014.01.038

Shamumugari, B., Srirawattananon, K., Wangkanont, K., and Phoolcharoen, W. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac. J. Allergy Immunol. 38, 10–18. doi: 10.12932/AP-2020-0773

Sogawa, K., Kobayashi, M., Suzuki, J., Snda, A., Kodera, Y., and Fukuyama, M. (2018). Inhibitory Activity of Hydroxytyrosol against Streptolysin O-Induced Hemolysis. Biocontrol Sci. 23, 77–80. doi: 10.4265/bio.23.77

Tanaka, T., Narazaki, M., and Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295. doi: 10.1001/cshperspect.a016295

U.S. Department of Health and Human Services (DHHS), FDA, Center for Drug Evaluation and Research (Cder) and Center for Biologics Evaluation and Research (CRER) (2014). FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products.
Usmani, S. S., Bedi, G., Samuel, J. S., Singh, S., Kalra, S., Kumar, P., et al. (2017). THPdb: Database of FDA-approved peptide and protein therapeutics. PloS One 12, e0181748. doi: 10.1371/journal.pone.0181748

Wingfield, P. T. (2017). N-Terminal Methionine Processing. Curr. Protoc. Protein Sci. 88, 6 14 11–16 14 13. doi: 10.1002/cpps.29

Zganiacz, A., Santosuosso, M., Wang, J., Yang, T., Chen, L., Anzulovic, M., et al. (2004). TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 113, 401–413. doi: 10.1172/JCI18991

**Conflict of Interest:** GP and SP are inventors on a patent application pertinent to this work (62/375,238).

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Esterly, Crilly, Piszkieiwicz, Shovlin, Pielak and Christian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**